抗米勒管激素和抑制素B在多囊卵巢综合征跨代效应中的研究进展

doi:10.12280/gjszjk.20250498

摘要/Abstract

摘要：

多囊卵巢综合征（polycystic ovary syndrome，PCOS）是一种常见的女性生殖内分泌紊乱性疾病，长期高雄激素水平的暴露可能会对子代的生殖、代谢及心理行为产生跨代影响。抗米勒管激素（anti-Müllerian hormone，AMH）和抑制素B（inhibin B，INHB）作为重要的生殖内分泌指标，因其影响PCOS子代生殖发育、代谢功能和精神发育，在PCOS发生发展、跨代效应及PCOS诊断中有重要作用。未来需进一步明确其作用机制，为PCOS跨代效应的早期识别、预防及治疗提供理论依据和实践策略。综述AMH与INHB的特征及其对PCOS子代的影响，旨在强调AMH与INHB作为PCOS子代疾病风险预测指标的潜力。

关键词: 多囊卵巢综合征, 抗苗勒管激素, 抑制素类, 跨代效应, 子代健康

Abstract:

Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting the female reproductive system. The prolonged exposure to elevated androgen may have transgenerational consequences on the reproductive, metabolic, and psychobehavioral characteristics of offspring. Anti-Müllerian hormone (AMH) and inhibin B (INHB), two of the key reproductive endocrine markers, are implicated in the PCOS pathogenesis and transgenerational effect, as well as the diagnosis of PCOS, because AMH and INHB influence reproductive development, metabolic function, and mental development in the offspring of PCOS. Future studies should clarify the mechanism of action, with the goal of providing a theoretical basis and practical strategies for the early identification, prevention, and management of PCOS-related transgenerational effects. We review the biological features of AMH and INHB, and examine their influence on thire offspring of PCOS, aiming to highlight their potential as predictive biomarkers for disease risk in these offspring.

Key words: Polycystic ovary syndrome, Anti-Mullerian hormone, Inhibins, Transgenerational effects, Offspring health

林拓, 宁舒婷, 花颖, 叶丽华, 马红霞. 抗米勒管激素和抑制素B在多囊卵巢综合征跨代效应中的研究进展[J]. 国际生殖健康/计划生育杂志, 2026, 45(1): 66-70.

LIN Tuo, NING Shu-ting, HUA Ying, YE Li-hua, MA Hong-xia. Research Progress on Anti-Müllerian Hormone and Inhibin B in the Transgenerational Effects of Polycystic Ovary Syndrome[J]. Journal of International Reproductive Health/Family Planning, 2026, 45(1): 66-70.

参考文献 31

[1]	Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome[J]. Eur J Endocrinol, 2023, 189(2):G43-G64. doi: 10.1093/ejendo/lvad096.
[2]	Liu Y, Dong Y, Jiang Y, et al. Caloric restriction prevents inheritance of polycystic ovary syndrome through oocyte-mediated DNA methylation reprogramming[J]. Cell Metab, 2025, 37(4):920-935.e6. doi: 10.1016/j.cmet.2025.01.014.
[3]	江楠, 赵晓丽, 徐佳淇, 等. 生殖障碍性疾病表观遗传机制的研究进展[J]. 中华医学遗传学杂志, 2024, 41(11):1393-1398. doi: 10.3760/cma.j.cn511374-20240524-00306.
[4]	Bhati P, Haloi P, Munjal K, et al. Polycystic ovary syndrome: Unveiling the multifaceted contributors, mechanisms, and psychological impacts[J]. Horm Behav, 2025, 176:105844. doi: 10.1016/j.yhbeh.2025.105844.
[5]	Kahn LG, Hipwell AE, Charifson M, et al. Maternal polycystic ovarian syndrome and offspring psychopathology and neurodevelopment[J]. Hum Reprod, 2025, 40(7):1257-1265. doi: 10.1093/humrep/deaf079.
[6]	Laven J. Polycystic ovary syndrome: antimüllerian hormone and its role in the pathophysiology of the syndrome[J]. Fertil Steril, 2025, 124(5 Pt 2):910-918. doi: 10.1016/j.fertnstert.2025.08.023.
[7]	Cotellessa L, Sobrino V, Silva M, et al. Preventing and correcting polycystic ovary syndrome by targeting anti-Müllerian hormone signaling in minipuberty and adulthood in mice[J]. Cell Metab, 2025, 37(6):1260-1276.e8. doi: 10.1016/j.cmet.2025.03.013.
[8]	Lu H, Jiang H, Li C, et al. Dissecting the Impact of Maternal Androgen Exposure on Developmental Programming through Targeting the Androgen Receptor[J]. Adv Sci(Weinh), 2024, 11(36):e2309429. doi: 10.1002/advs.202309429.
[9]	连超, 周宇, 居蓉, 等. PCOS患者妊娠期过量睾酮影响男性子代生殖发育的机制研究进展[J]. 中华生殖与避孕杂志, 2024, 44(5):541-547. doi: 10.3760/cma.j.cn101441-20230614-00238.
[10]	刘宏颖, 伍学焱. 抗苗勒管激素在男性不育疾病诊疗中的研究进展[J]. 中华医学杂志, 2025, 105(29):2521-2525. doi: 10.3760/cma.j.cn112137-20250316-00644.
[11]	蔡芸莹, 苏恒. 抗苗勒管激素在儿童及青少年性发育异常疾病诊断中的应用进展[J]. 国际内分泌代谢杂志, 2023, 43(1):58-61. doi: 10.3760/cma.j.cn121383-20211107-11020.
[12]	Tzeng CR, Huang Z, Asada Y, et al. Factors affecting the distribution of serum anti-müllerian hormone levels among infertile Asian women: a multi-nation, multi-centre, and multi-ethnicity prospective cohort study[J]. Hum Reprod, 2023, 38(7):1368-1378. doi: 10.1093/humrep/dead081.
[13]	La Marca A, Capuzzo M, Imbrogno MG, et al. The complex relationship between female age and embryo euploidy[J]. Minerva Obstet Gynecol, 2021, 73(1):103-110. doi: 10.23736/S2724-606X.20.04740-1.
[14]	Jankowska K, Suszczewicz N, Rabijewski M, et al. Inhibin-B and FSH Are Good Indicators of Spermatogenesis but Not the Best Indicators of Fertility[J]. Life(Basel), 2022, 12(4):511. doi: 10.3390/life12040511.
[15]	徐慧玉, 李蓉. 从实验室到临床:AMH和抑制素B在女性生殖健康的变革力量[J]. 中华生殖与避孕杂志, 2025, 45(1):5-13. doi: 10.3760/cma.j.cn101441-20241112-00414.
[16]	Barbotin AL, Ballot C, Sigala J, et al. The serum inhibin B concentration and reference ranges in normozoospermia[J]. Eur J Endocrinol, 2015, 172(6):669-676. doi: 10.1530/EJE-14-0932.
[17]	Fiçicioğlu C, Kutlu T, Demirbaşoğlu S, et al. The role of inhibin B as a basal determinant of ovarian reserve[J]. Gynecol Endocrinol, 2003, 17(4):287-293. pmid: 14503972
[18]	张倩岚, 岳朝艳, 应春妹. 血清AMH与抑制素B检测对多囊卵巢综合征的辅助诊断应用[J]. 中华检验医学杂志, 2019, 42(8):652-656. doi: 10.3760/cma.j.issn.1009-9158.2019.08.013.
[19]	Mimouni N, Giacobini P. Polycystic ovary syndrome (PCOS): progress towards a better understanding and treatment of the syndrome[J]. C R Biol, 2024, 347:19-25. doi: 10.5802/crbiol.147.
[20]	邱喻兰, 刘杉. 西南地区男/女儿童血清抗米勒管激素水平医学参考值范围的建立[J]. 重庆医学, 2023, 52(4):537-540. doi: 10.3969/j.issn.1671-8348.2023.04.012.
[21]	王斐, 张泓, 刘庆旭, 等. 1 400名0-5岁健康儿童血清抗苗勒氏管激素及抑制素B临床检测研究[J]. 中国实用儿科杂志, 2016, 31(6):450-454. doi: 10.7504/ek2016060612.
[22]	Pavli P, Kalampokas T, Eleftheriades M, et al. Daughters of PCOS mothers and AMH plasma concentrations in pre-puberty and puberty: A meta-analysis[J]. Early Hum Dev, 2025, 201:106194. doi: 10.1016/j.earlhumdev.2025.106194.
[23]	Recabarren SE, Sir-Petermann T, Rios R, et al. Pituitary and testicular function in sons of women with polycystic ovary syndrome from infancy to adulthood[J]. J Clin Endocrinol Metab, 2008, 93(9):3318-3324. doi: 10.1210/jc.2008-0255.
[24]	Dong Y, Dai L, Dong Y, et al. Analysis of risk factors of precocious puberty in children[J]. BMC Pediatr, 2023, 23(1):456. doi: 10.1186/s12887-023-04265-x. pmid: 37697362
[25]	赵永新, 周英, 李庆业, 等. 多囊卵巢综合征患者雄激素水平与抗苗勒管激素、抑制素B水平的关系研究[J]. 中华生物医学工程杂志, 2020, 26(2):97-101. doi: 10.3760/cma.j.cn115668-20191126-00097.
[26]	Rojas-García PP, Recabarren MP, Sarabia L, et al. Prenatal testosterone excess alters Sertoli and germ cell number and testicular FSH receptor expression in rams[J]. Am J Physiol Endocrinol Metab, 2010, 299(6):E998-E1005. doi: 10.1152/ajpendo.00032.2010.
[27]	Crisosto N, Echiburú B, Maliqueo M, et al. Reproductive and metabolic features during puberty in sons of women with polycystic ovary syndrome[J]. Endocr Connect, 2017, 6(8):607-613. doi: 10.1530/EC-17-0218. pmid: 28912339
[28]	Risal S, Li C, Luo Q, et al. Transgenerational transmission of reproductive and metabolic dysfunction in the male progeny of polycystic ovary syndrome[J]. Cell Rep Med, 2023, 4(5):101035. doi: 10.1016/j.xcrm.2023.101035.
[29]	窦攀, 张婷婷, 徐阳, 等. 三种医学营养减重法对超重或肥胖多囊卵巢综合征患者代谢参数和雄激素水平的影响[J]. 中华医学杂志, 2023, 103(14): 1035-1041. doi: 10.3760/cma.j.cn112137-20220930-02066.
[30]	Baron-Cohen S, Auyeung B, Nørgaard-Pedersen B, et al. Elevated fetal steroidogenic activity in autism[J]. Mol Psychiatry, 2015, 20(3):369-376. doi: 10.1038/mp.2014.48.
[31]	Kosidou K, Dalman C, Widman L, et al. Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden[J]. Mol Psychiatry, 2016, 21(10):1441-1448. doi: 10.1038/mp.2015.183.